LON:STX - Shield Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 81.50 +4.00 (+5.16 %)
(As of 04/21/2019 06:57 AM ET)
Previous CloseGBX 81.50
Today's RangeGBX 78 - GBX 82
52-Week RangeGBX 15.02 - GBX 83
Volume118,332 shs
Average Volume48,665 shs
Market Capitalization£95.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-191-5118500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£11.88 million
Cash FlowGBX 8.40 per share
Book ValueGBX 34.70 per share

Profitability

Miscellaneous

Employees15
Market Cap£95.21 million
Next Earnings DateN/A
OptionableOptionable

Shield Therapeutics (LON:STX) Frequently Asked Questions

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

What price target have analysts set for STX?

2 Wall Street analysts have issued 12-month target prices for Shield Therapeutics' shares. Their forecasts range from GBX 88 to GBX 116. On average, they anticipate Shield Therapeutics' share price to reach GBX 102 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for Shield Therapeutics.

What is the consensus analysts' recommendation for Shield Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.

Has Shield Therapeutics been receiving favorable news coverage?

News stories about STX stock have been trending positive on Sunday, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Shield Therapeutics earned a news impact score of 2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Shield Therapeutics' key competitors?

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Geron (GERN), Micron Technology (MU), Lendlease Group (LLC), Velocity Data (VCT), Ctrip.Com International (CTRP) and AAR (AIR).

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the folowing people:
  • Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
  • Mr. Timothy William Watts, Chief Financial Officer (Age 61)
  • Fleur Wood, Director of Investor Relations
  • Ms. Lucy Bailey, Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood, Group HR Director

How do I buy shares of Shield Therapeutics?

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 81.50.

How big of a company is Shield Therapeutics?

Shield Therapeutics has a market capitalization of £95.21 million and generates £11.88 million in revenue each year. Shield Therapeutics employs 15 workers across the globe.

What is Shield Therapeutics' official website?

The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.


MarketBeat Community Rating for Shield Therapeutics (LON STX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel